Cellebrite DI Q3 Adj EPS $0.09 Beats $0.05 Estimate, Sales $84.18M Beat $82.13M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cellebrite DI (NASDAQ:CLBT) reported Q3 adjusted EPS of $0.09, surpassing the $0.05 estimate, marking an 80% beat and an 800% increase from $0.01 per share last year. Sales reached $84.18M, exceeding the $82.13M estimate by 2.49% and showing a 17.45% increase from $71.67M in the same period last year.
November 14, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellebrite DI reported strong Q3 earnings with significant beats on both EPS and revenue estimates, indicating robust financial performance.
The substantial earnings and sales beat by Cellebrite DI suggests a positive outlook for the company's financial health, which is likely to be well-received by investors. The 800% increase in EPS and 17.45% increase in sales compared to the same period last year are strong indicators of growth, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100